Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
VSTM's Cash to Debt is ranked higher than
80% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. VSTM: No Debt )
VSTM' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
VSTM's Interest Coverage is ranked higher than
62% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VSTM: No Debt )
VSTM' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: 11.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -46.85
VSTM's ROE (%) is ranked higher than
69% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. VSTM: -46.85 )
VSTM' s 10-Year ROE (%) Range
Min: -82.33   Max: -39.63
Current: -46.85

-82.33
-39.63
ROA (%) -43.84
VSTM's ROA (%) is ranked higher than
66% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. VSTM: -43.84 )
VSTM' s 10-Year ROA (%) Range
Min: -42.1   Max: -37.77
Current: -43.84

-42.1
-37.77
ROC (Joel Greenblatt) (%) -4076.25
VSTM's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. VSTM: -4076.25 )
VSTM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7948.21   Max: -5742.3
Current: -4076.25

-7948.21
-5742.3
» VSTM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

VSTM Guru Trades in Q4 2013

Paul Tudor Jones 17,219 sh (New)
Jean-Marie Eveillard 511,254 sh (+3.77%)
Jim Simons Sold Out
Steven Cohen Sold Out
» More
Q1 2014

VSTM Guru Trades in Q1 2014

Jean-Marie Eveillard 511,254 sh (unchged)
Paul Tudor Jones 11,685 sh (-32.14%)
» More
Q2 2014

VSTM Guru Trades in Q2 2014

Jean-Marie Eveillard 512,254 sh (+0.2%)
Paul Tudor Jones Sold Out
» More
Q3 2014

VSTM Guru Trades in Q3 2014

Jim Simons 66,300 sh (New)
Jean-Marie Eveillard 512,254 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with VSTM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-09-30 New Buy0.02%$12.71 - $17.57 $ 8.34-43%492703
Jean-Marie Eveillard 2013-06-30 Sold Out $8.79 - $13.88 $ 8.34-17%0
Jean-Marie Eveillard 2012-09-30 Add 54.31%$8.02 - $11.5 $ 8.34-12%52331
Jean-Marie Eveillard 2012-06-30 New Buy$9.3 - $11.11 $ 8.34-17%33912
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.40
VSTM's P/B is ranked higher than
86% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. VSTM: 2.40 )
VSTM' s 10-Year P/B Range
Min: 0   Max: 4.9
Current: 2.4

0
4.9
EV-to-EBIT -2.38
VSTM's EV-to-EBIT is ranked higher than
52% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. VSTM: -2.38 )
VSTM' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -2.38

Current Ratio 11.27
VSTM's Current Ratio is ranked higher than
89% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. VSTM: 11.27 )
VSTM' s 10-Year Current Ratio Range
Min: 11.13   Max: 30.79
Current: 11.27

11.13
30.79
Quick Ratio 11.27
VSTM's Quick Ratio is ranked higher than
89% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. VSTM: 11.27 )
VSTM' s 10-Year Quick Ratio Range
Min: 11.13   Max: 30.79
Current: 11.27

11.13
30.79

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.60
VSTM's Price/Net Cash is ranked higher than
95% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. VSTM: 2.60 )
VSTM' s 10-Year Price/Net Cash Range
Min: 2.57   Max: 6.04
Current: 2.6

2.57
6.04
Price/Net Current Asset Value 2.60
VSTM's Price/Net Current Asset Value is ranked higher than
95% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. VSTM: 2.60 )
VSTM' s 10-Year Price/Net Current Asset Value Range
Min: 2.57   Max: 6.04
Current: 2.6

2.57
6.04
Price/Tangible Book 2.40
VSTM's Price/Tangible Book is ranked higher than
90% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. VSTM: 2.40 )
VSTM' s 10-Year Price/Tangible Book Range
Min: 1.98   Max: 3.87
Current: 2.4

1.98
3.87
Earnings Yield (Greenblatt) -41.30
VSTM's Earnings Yield (Greenblatt) is ranked higher than
53% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. VSTM: -41.30 )
VSTM' s 10-Year Earnings Yield (Greenblatt) Range
Min: -41.5   Max: 0
Current: -41.3

-41.5
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:2VS.Germany,
Verastem Inc was incorporated under the laws of the State of Delaware in August 2010. The Company is a biopharmaceutical company engaged in discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. A cancer stem cell is a particularly aggressive type of tumor cell, resistant to conventional cancer therapy, that it believes is an underlying cause of tumors, their recurrence and metastasis. It licenses its EMT technology from the Whitehead Institute for Biomedical Research, an affiliate of the Massachusetts Institute of Technology, or MIT, and the President and Fellows of Harvard College, or Harvard. Its advanced product candidates are VS-6063, VS-4718 and VS-5584. It is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including mesothelioma, ovarian and lung. The Company's solution is to discover and develop a next generation of oncology therapeutics targeting CSCs along with companion diagnostics. It believes that by developing therapeutics that target CSCs it can address the problem of cancer recurrence and metastasis. The Company has three product candidates currently in clinical trials including the focal adhesion kinase (FAK) inhibitors VS-6063 and VS-4718, and the dual mTORC1/2 and PI3K inhibitor VS-5584. The Company's competitors include Astellas Pharma Inc., Celgene, Inc., Sanofi-Aventis U.S. LLC, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Pfizer Inc. and others. There are also biotechnology companies of various sizes that are developing therapies against CSCs, including OncoMed Pharmaceuticals, Inc., Boston Biomedical Inc. (a division of Dainippon Sumitomo Corp) and Stemline Therapeutics, Inc. and others. The Company is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes.
» More Articles for VSTM

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Verastem Presents Data at the 2014 San Antonio Breast Cancer Symposium Dec 11 2014
Verastem Presents Data at the 2014 San Antonio Breast Cancer Symposium Dec 11 2014
Verastem Presents Data at the 2014 American Society of Hematology Annual Meeting Dec 08 2014
Verastem Presents Data at the 2014 American Society of Hematology Annual Meeting Dec 08 2014
Verastem to Present Data at the 2014 San Antonio Breast Cancer Symposium Dec 04 2014
Verastem to Present Data at the 2014 San Antonio Breast Cancer Symposium Dec 04 2014
Verastem to Participate in Upcoming Investor Conferences Dec 03 2014
Verastem to Participate in Upcoming Investor Conferences Dec 03 2014
Verastem to Present Data at the 2014 American Society of Hematology Annual Meeting Dec 01 2014
Verastem to Present Data at the 2014 American Society of Hematology Annual Meeting Dec 01 2014
ProQR Therapeutics Announces Results for the Third Quarter of 2014 Nov 24 2014
Verastem Presents Data at the 2014 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer... Nov 21 2014
Verastem Presents Data at the 2014 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer... Nov 21 2014
Verastem to Present Data at the 2014 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer... Nov 13 2014
Verastem to Present at the Jefferies 2014 Global Healthcare Conference Nov 13 2014
Verastem to Present at the Jefferies 2014 Global Healthcare Conference Nov 13 2014
Verastem to Participate in Panel at the MassBio Patient Advocacy Summit Nov 10 2014
Verastem To Participate In Panel At The MassBio Patient Advocacy Summit Nov 10 2014
Verastem to Participate in Panel at the MassBio Patient Advocacy Summit Nov 10 2014
Scientific Data on PYK2 Inhibition by VS-4718 in Multiple Myeloma Published in the Journal Blood Nov 07 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK